Analysis of Prognostic Factors and Comparison of Prognostic Index Scores in Patients with Brain Metastases After Whole-brain Radiotherapy

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Feb 10

PMID 25664024

Citations 3

Authors

Judong Luo

Hong Zhu

Yiting Tang

Honglin Wang

Xifa Zhou

Xujing Lu

Shuyu Zhang

Yunhai Li

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Brain metastases (BMs) are typically associated with poor patient prognosis. Radiation therapy remains the primary treatment for BMs, and patient's prognosis is affected by many factors. The aim of this study was to identify prognostic factors and to compare prognostic index scores in patients with BMs who received whole-brain radiotherapy (WBRT).

Methods: A retrospective prognostic study was conducted in 125 patients with BMs who underwent WBRT between Jan 2008 and Jul 2011. The significance of prognostic variables with regard to survival was determined using univariate and multivariate analyses. A prognostic index (PI) was established based on Cox regression analysis and subgrouping values. The recursive partitioning analysis classes (RPA), basic score for brain metastases (BS-BM), Graded Prognostic Assessment index (GPA), and PI were assessed with regard to prognosis.

Results: The median survival time was 213 days (7.1 months). In the univariate analysis of the test group, survival was significantly associated with Karnofsky performance status (KPS) score, the number of BMs, the presence of extracranial metastases, primary tumor status and the number of involved extracranial organs. The multivariate analysis showed that the KPS score (P = 0.002, Wald = 9.700), presence of extracranial metastases (P = 0.018, Wald = 5.604) and primary tumor status (P = 0.001, Wald = 10.212) were significantly correlated with overall survival. RPA, BS-BM and GPA were all closely related to prognosis, as determined using a log-rank test. In predicting the 3- and 6-month survival for patients, the PI was superior to the other three modes.

Conclusions: The three indexes, RPA, BS-BM and GPA, are valid prognostic index models; however, the PI model was the most powerful.

Citing Articles

Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery.

Gao H, Huang S, Du J, Zhang X, Jiang N, Kang W Int J Biol Sci. 2018; 14(14):2065-2072.

PMID: 30585269 PMC: 6299364. DOI: 10.7150/ijbs.28608.

The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis.

Kim H, Lee K, Heo M, Kim J Korean J Intern Med. 2018; 34(6):1324-1332.

PMID: 30360020 PMC: 6823565. DOI: 10.3904/kjim.2018.051.

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis.

Lu Y, Fan Y Onco Targets Ther. 2016; 9:1135-43.

PMID: 27022274 PMC: 4790505. DOI: 10.2147/OTT.S95871.

References

Arruda Viani G, Silva L, Stefano E . Prognostic indexes for brain metastases: which is the most powerful?. Int J Radiat Oncol Biol Phys. 2012; 83(3):e325-30. DOI: 10.1016/j.ijrobp.2011.12.082. View

Gallego Perez-Larraya J, Hildebrand J . Brain metastases. Handb Clin Neurol. 2013; 121:1143-57. DOI: 10.1016/B978-0-7020-4088-7.00077-8. View

Dziggel L, Segedin B, Podvrsnik N, Oblak I, Schild S, Rades D . Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol. 2013; 189(5):364-6. DOI: 10.1007/s00066-013-0308-3. View

Nieder C, Bremnes R, Andratschke N . Prognostic scores in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol. 2009; 4(11):1337-41. DOI: 10.1097/JTO.0b013e3181b6b6f4. View

Antoni D, Clavier J, Pop M, Schumacher C, Lefebvre F, Noel G . Institutional, retrospective analysis of 777 patients with brain metastases: treatment outcomes and diagnosis-specific prognostic factors. Int J Radiat Oncol Biol Phys. 2013; 86(4):630-7. DOI: 10.1016/j.ijrobp.2013.02.027. View

Yamamoto M, Sato Y, Serizawa T, Kawabe T, Higuchi Y, Nagano O . Subclassification of recursive partitioning analysis Class II patients with brain metastases treated radiosurgically. Int J Radiat Oncol Biol Phys. 2012; 83(5):1399-405. DOI: 10.1016/j.ijrobp.2011.10.018. View

Rades D, Gerdan L, Segedin B, Nagy V, Khoa M, Trang N . Brain metastasis. Prognostic value of the number of involved extracranial organs. Strahlenther Onkol. 2013; 189(12):996-1000. DOI: 10.1007/s00066-013-0442-y. View

Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W . A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2007; 70(2):510-4. DOI: 10.1016/j.ijrobp.2007.06.074. View

Welsh J, Komaki R, Amini A, Munsell M, Unger W, Allen P . Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013; 31(7):895-902. PMC: 3577951. DOI: 10.1200/JCO.2011.40.1174. View

10.

Nieder C, Pawinski A, Molls M . Prediction of short survival in patients with brain metastases based on three different scores: a role for 'triple-negative' status?. Clin Oncol (R Coll Radiol). 2009; 22(1):65-9. DOI: 10.1016/j.clon.2009.08.011. View

11.

Sperduto C, Watanabe Y, Mullan J, Hood T, Dyste G, Watts C . A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg. 2009; 109 Suppl:87-9. DOI: 10.3171/JNS/2008/109/12/S14. View

12.

Zhuang H, Wang J, Zhao L, Yuan Z, Wang P . The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int J Cancer. 2013; 133(10):2277-83. DOI: 10.1002/ijc.28290. View

13.

Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vanderlinden B . Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004; 60(1):218-24. DOI: 10.1016/j.ijrobp.2004.02.017. View

14.

Eichler A, Kuter I, Ryan P, Schapira L, Younger J, Henson J . Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer. 2008; 112(11):2359-67. DOI: 10.1002/cncr.23468. View

15.

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

16.

Saito E, Viani G, Ferrigno R, Nakamura R, Novaes P, Pellizzon C . Whole brain radiation therapy in management of brain metastasis: results and prognostic factors. Radiat Oncol. 2006; 1:20. PMC: 1526744. DOI: 10.1186/1748-717X-1-20. View

17.

Sperduto P, Chao S, Sneed P, Luo X, Suh J, Roberge D . Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2009; 77(3):655-61. DOI: 10.1016/j.ijrobp.2009.08.025. View

18.

Kondziolka D, Parry P, Lunsford L, Kano H, Flickinger J, Rakfal S . The accuracy of predicting survival in individual patients with cancer. J Neurosurg. 2013; 120(1):24-30. DOI: 10.3171/2013.9.JNS13788. View

19.

Chidel M, Suh J, Reddy C, Chao S, Lundbeck M, Barnett G . Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys. 2000; 47(4):993-9. DOI: 10.1016/s0360-3016(00)00527-7. View

20.

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View